When tumor-bearing mice were immunized with the neu DNA plasmid or IDO siRNA alone, tumor growth was significantly slower compared to the control, but when mice were treated with the fusion neu-IDO siRNA plasmid, the mice had significantly longer survival compared to either neu vaccine or IDO siRNA alone [134]. The gene discussed is ERBB2; the disease is neoplasm.